Creative Medical announces interim data from ADAPT trial of CELZ-201

Creative Medical (CELZ) Technology Holding announced interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201, the Company’s proprietary perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease. The study produced statistically significant, clinically meaningful improvements in both functional disability and pain at primary trial end point, confirming durable human efficacy alongside an excellent safety profile. The announcement of this data follows a previously announced study enrollment completion and positive independent Data Safety Monitoring Board safety review, which confirmed that CELZ-201 demonstrated a favorable safety profile with no significant adverse events and supported continued advancement of the trial. Key Clinical Outcomes at Interim Analysis: ODI%: Mean improvement of -15.3 percentage points at 180 days. Approximately 79% of patients achieved clinically meaningful functional improvement. Pain: Mean reduction of -3.9 points at 180 days. Approximately 79% of patients achieved greater than or equal to2-point pain reduction. Safety: Independent DSMB review confirmed no serious adverse events and no treatment-related safety signals, remaining blinded 4:1 treatment: placebo.